SKYE
Skye Bioscience, Inc.1.1900
+0.1100+10.2%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
38.15MP/E (TTM)
-Basic EPS (TTM)
-1.30Dividend Yield
0%Recent Filings
8-K
Nimacimab boosts semaglutide weight loss
Skye Bioscience unveiled Q3 topline data from its CBeyond Phase 2a trial, revealing nimacimab plus semaglutide delivered 29% greater weight loss than semaglutide alone after 26 weeks, plus an extra 3.2 cm waist reduction and blunted post-treatment rebound. Cash stands at $35.3 million, funding ops into 2027; R&D expenses jumped to $9.4 million amid trial ramp-up, driving $12.8 million net loss. Extension data due Q1 2026.
10-Q
Q3 FY2025 results
Skye Bioscience posted a Q3 operating loss of $13.3M, up from $5.0M a year ago, driven by R&D ramp to $9.4M (nimacimab $6.9M) while G&A fell to $3.9M; nine-month operating loss hit $43.3M versus $19.5M prior year. Net loss steepened to $12.8M ($0.32/share) from $3.9M ($0.10/share), matching diluted shares of 39.7M. Cash burned $33.3M on operations with minimal capex, leaving $18.4M cash plus $16.9M short-term investments at quarter-end September 30, 2025. Cash runway shrinks fast. Legal contingency lingers at $2.1M ahead of February 2026 retrial. Nimacimab combo data impressed. Ongoing litigation risks a cash drain.
8-K
Nimacimab combo boosts weight loss
Skye Bioscience announced topline results from its 26-week Phase 2a CBeyond trial on October 6, 2025, showing nimacimab monotherapy at 200 mg failed to meet the primary weight loss endpoint, achieving just -1.52% versus -0.26% for placebo due to suboptimal drug exposure. Yet the combination with semaglutide delivered clinically meaningful extra weight loss of -13.2% compared to -10.25% for semaglutide alone, with no added GI or neuropsychiatric side effects. Nimacimab proved safe. Higher doses look promising.
8-K
Skye Q2 loss widens on R&D
Skye Bioscience reported Q2 2025 net loss of $17.6 million, up from $7.9 million last year, driven by $14.3 million in R&D expenses for nimacimab's obesity trial. Cash reserves stand at $48.6 million, funding operations through Q1 2027. Preclinical data show nimacimab's combo with low-dose tirzepatide yields 44% vehicle-adjusted weight loss, outperforming optimal tirzepatide alone. Top-line Phase 2a results due late Q3/early Q4 2025. Enrollment advances in extension study.
10-Q
Q2 FY2025 results
Skye Bioscience ramped up R&D spending to $14.3M in Q2 FY2025 ended June 30, 2025, driving an operating loss of $18.2M, up 117% y/y from $8.4M, while net loss widened to $17.6M from $7.9M, with the gap mainly from $2.0M stock-based compensation. For the half-year, R&D hit $21.5M (up 257% y/y), fueling a $30.0M operating loss and $28.7M net loss versus $14.6M and $12.9M last year; diluted EPS fell to $(0.72) on 39.7M shares, consistent with calculations. Cash burn accelerated to $19.9M from operations, leaving $23.8M in cash equivalents plus $24.7M short-term investments, with no debt but a $1.8M legal contingency from ongoing litigation. The nimacimab Phase 2a trial advances toward top-line data late 2025. Cash lasts at least 12 months. Yet clinical trial delays loom large.
ALT
Altimmune, Inc.
5.03-0.25
ENVB
Enveric Biosciences, Inc.
5.24-0.12
IMA
ImageneBio, Inc.
6.25+0.08
KALA
KALA BIO, Inc.
0.56-0.05
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16
MTSR
Metsera, Inc.
70.50-0.25
OKYO
OKYO Pharma Limited
1.88-0.01
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SGMT
Sagimet Biosciences Inc. - Seri
6.05+0.02
SPRC
SciSparc Ltd.
1.61-0.03